Correction: In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

In this article (Mol Cancer Ther 2014;13:2040–49), which appeared in the August 2014 issue of Molecular Cancer Therapeutics (1), the authors request a revision of the following text on page 2041 of the article:

In addition, 7 mutations in domain III (R505A, R427A, R490A, R467A, D463A, R458A, and R538A) were introduced to silence previously identified B-cell epitopes (14).

The revised text is as follows:

In addition, 7 mutations in domain III (R505A, R427A, R490A, R467A, D463A, R538A, and R456A) were introduced to silence identified B-cell epitopes. Six of these mutations are identical to those included in the previously reported LR-LO10 PE moiety: R505A, R427A, R490A, R467A, D463A, and R538A (14). The seventh mutation originally introduced in LR-LO10, R458A, was later found to lead to loss of activity and therefore not included in RG7787. As an alternative and to destroy the targeted B-cell epitope, we focused on changing nearby residues of R458. In the structure of domain III, R456 is close to R458 and was therefore mutated to A. We found that R456A was more active than R458A and also destroyed the B-cell epitope.

Additionally, mutation 456A is incorrectly labeled as 458A in Fig. 1 and in the Fig. 1 legend.